Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

THG paints confident outlook after returning to sales growth

(Sharecast News) - Ecommerce conglomerate THG has reiterated full-year guidance after reporting a return to growth in the second quarter, with further improvements in revenues expected from both sides of the business in the second half. THG, which owns brands like Myprotein, Cult Beauty and Glossybox, saw first-half sales across the business fall 2.6% at constant currencies (CCY), as a 3.1% increase in the Nutrition division was offset by a 5.9% decline in the larger Beauty division.

However, the company reported a turnaround in the second quarter, with CCY sales growing by 0.9% after dropping 6.1% in the first quarter.

Looking ahead, THG expects Beauty and Nutrition CCY sales to rise by 1-3% and 10-12% in the second half, respectively.

"I'm really pleased at how THG has gained momentum throughout the first half and into Q3. A slower start to the year in Beauty, alongside record whey prices in Nutrition, initially held back performance, but we saw clear improvement in Q2, in particular supported by Myprotein offline retail and licensing sales," said chief executive Matthew Moulding.

"Our momentum is positive and Q3 will be our strongest trading period of the year so far, underpinning our confidence in the outlook."

Results for the six months to 30 June, which were well flagged in recent trading updates, showed revenues of £783.4m, down 7.6% on last year on a reported basis, while adjusted EBITDA sank 35.3% to £24m.

On the bright side, net debt reduced to £321.4m by period-end, from £350.5m the year before, and fell further to £220m as a result of the recent sale of its Claremont Ingredients subsidiary.

Shares were down 0.6% at 28.5p in early deals on Thursday.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.